other material
confidence high
sentiment positive
materiality 0.60
iBio Reports Preclinical Data for IBIO-610 Showing Extended Half-Life in Obese Non-Human Primates
iBio, Inc.
- IBIO-610 half-life in obese NHP measured at 33.2 days.
- Predicted human half-life up to 100 days, enabling twice-yearly dosing.
- Data to be presented at ObesityWeek 2025, Nov 4-7 in Atlanta by Cory Schwartz, Ph.D.
- IBIO-610 is a potential first-in-class Activin E antibody for fat-selective weight loss.
- Previously showed GLP-1-synergistic weight loss and prevention of weight regain in mouse models.